FOR RESEARCH USE ONLY
Clinical trial literatureMitochondrial research

SS-31

Mitochondrial-targeted tetrapeptide (Elamipretide) researched for cardiolipin stabilisation, cellular energy and age-related mitochondrial decline.

01Cardiolipin02Mitochondrial cristae03ATP production
Molecular signature / ss-31
Structural identity

Aromatic-cationic tetrapeptide targeting the inner mitochondrial membrane

Also known as

Elamipretide · MTP-131 · Bendavia

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

SS-31 (also known as Elamipretide, MTP-131 or Bendavia) is a synthetic aromatic-cationic tetrapeptide (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane at levels up to 1,000-fold higher than in the cytosol. It binds cardiolipin — a phospholipid unique to mitochondria — stabilising cristae architecture, protecting electron-transport-chain integrity and restoring ATP production in dysfunctional mitochondria. It has progressed through Phase 3 clinical trials for Barth syndrome, primary mitochondrial myopathy, dry AMD and heart failure with preserved ejection fraction (HFpEF).

The research question

SS-31 concentrates at cardiolipin-rich mitochondrial membranes rather than acting as a general antioxidant. Cristae structure, respiratory-chain organisation and ATP output are therefore more relevant measurements than a generic oxidative-stress score.

Section 02

Mechanism & research themes

Selectively binds cardiolipin in the inner mitochondrial membrane, stabilising cristae structure and optimising the supercomplex assembly of Complexes I–IV. This restores efficient electron flow, reduces mitochondrial reactive oxygen species (ROS) generation at source, preserves the inner-membrane potential and rescues ATP synthesis. Uniquely, uptake does not require an active membrane potential — allowing it to enter and rescue already-injured mitochondria.

01

Cardiolipin stabilisation and cristae-architecture preservation

02

Restored ATP synthesis in dysfunctional mitochondria

03

Reduced mitochondrial ROS generation at source (not just downstream scavenging)

04

Phase 2/3 data in Barth syndrome, primary mitochondrial myopathy and dry AMD

05

Investigated for HFpEF, ischaemia-reperfusion injury and diabetic nephropathy

06

Emerging research signals in age-related mitochondrial decline and sarcopenia

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Clinical trial literature

Human trials span several mitochondrial and cardiovascular indications, with mixed efficacy results by endpoint and condition. The mechanism is well described, but success in one indication cannot be assumed in another.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 3–5mg subcutaneously once daily. Clinical trial dosing has ranged from 4mg to 40mg/day SC across indications (Barth syndrome, mitochondrial myopathy, HFpEF). Cycles typically run 4–12 weeks; longer daily-use protocols are cited in mitochondrial-disease research. Rotate injection sites.

Reported persistence

Plasma half-life approximately 2–4 hours; mitochondrial tissue residence and biological effect persists significantly longer through cardiolipin binding.

Calculator starting point

5 mg per reference dose

7 doses per week · 8-week cycle

3 mL default reconstitution volume

3–5 mg/day SC typical; clinical dosing ranges 4–40 mg/day depending on indication.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate SS-31
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 30mg vial with 3mL bacteriostatic water for a 10mg/mL working concentration (0.1mL = 1mg). Swirl gently down the side of the vial — do not shake.

Storage reference

Lyophilised: 2–8°C, stable approximately 24 months; -20°C for long-term. Avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Injection-site reactions (redness, itching, induration) are the most common event across clinical trials.

L2

Phase 3 MMPOWER-3 (primary mitochondrial myopathy) missed its primary endpoint; efficacy varies by indication.

L3

Not FDA-approved; some Phase 3 programs remain ongoing. Long-term human safety data beyond trial durations remains limited.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only